Engel, A. G., Shen, X.-M., Selcen, D. & Sine, S. M. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol. 14, 420–434 (2015).
Google Scholar
Li, H., Teng, J. & Hibbs, R. E. Structural switch in acetylcholine receptors in developing muscle. Nature 632, 1174–1180 (2024).
Google Scholar
Ramdas, S., Beeson, D. & Dong, Y. Y. Congenital myasthenic syndromes: increasingly complex. Curr. Opin. Neurol. 37, 493–501 (2024).
Rodríguez Cruz, P. M., Palace, J. & Beeson, D. The neuromuscular junction and wide heterogeneity of congenital myasthenic syndromes. Int. J. Mol. Sci. 19, 1677 (2018).
Shen, X.-M. et al. Mutation causing severe myasthenia reveals functional asymmetry of AChR signature cystine loops in agonist binding and gating. J. Clin. Investig. 111, 497–505 (2003).
Google Scholar
Shen, X.-M., Brengman, J. M., Edvardson, S., Sine, S. M. & Engel, A. G. Highly fatal fast-channel syndrome caused by AChR ɛ subunit mutation at the agonist binding site. Neurology 79, 449–454 (2012).
Google Scholar
Cetin, H., Beeson, D., Vincent, A. & Webster, R. The structure, function, and physiology of the fetal and adult acetylcholine receptor in muscle. Front. Mol. Neurosci. 13, 581097 (2020).
Engel, A. G. The therapy of congenital myasthenic syndromes. Neurotherapeutics 4, 252–257 (2007).
Google Scholar
Engel, A. G., Ohno, K. & Sine, S. M. Sleuthing molecular targets for neurological diseases at the neuromuscular junction. Nat. Rev. Neurosci. 4, 339–352 (2003).
Google Scholar
Lee, M., Beeson, D. & Palace, J. Therapeutic strategies for congenital myasthenic syndromes. Ann. N. Y. Acad. Sci. 1412, 129–136 (2018).
Google Scholar
Sine, S. M. et al. Mechanistic diversity underlying fast channel congenital myasthenic syndromes. Ann. N. Y. Acad. Sci. 998, 128–137 (2003).
Google Scholar
Rahman, M. M. & Fatema, K. Fast channel congenital myesthenic syndrome: reporting two cases with mutation of CHRNE gene and short review. J. Pediatric Neurosci. 17, 160–163 (2022).
Mallappa, A., Tirupathi, S., Boyd, J., B’Connor, O. & Illingworth, M. 661 Fast channel syndrome: presentation, diagnosis and management in an infant. Pediatr. Res. 68, 338–338 (2010).
Google Scholar
Palace, J. et al. Clinical features in a series of fast channel congenital myasthenia syndrome. Neuromuscul. Disord. 22, 112–117 (2012).
Google Scholar
Palace, J., Wiles, C. M. & Newsom-Davis, J. 3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia. J. Neurol. Neurosurg. Psychiatry 54, 1069 (1991).
Google Scholar
Kao, J. C. et al. Congenital myasthenic syndromes in adult neurology clinic. Neurology 91, e1770–e1777 (2018).
Google Scholar
Dowling, J. J., D. Gonorazky, H., Cohn, R. D. & Campbell, C. Treating pediatric neuromuscular disorders: the future is now. Am. J. Med. Genet. Part A 176, 804–841 (2018).
Google Scholar
Li, A. et al. Structures of the human adult muscle-type nicotinic receptor in resting and desensitized states. Cell Rep. 44, 5115581 (2025).
Bertrand, D. & Gopalakrishnan, M. Allosteric modulation of nicotinic acetylcholine receptors. Biochem. Pharmacol. 74, 1155–1163 (2007).
Google Scholar
Engel, A. G. et al. A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann. Neurol. 11, 553–569 (1982).
Google Scholar
Fukudome, T., Ohno, K., Brengman, J. M. & Engel, A. G. Quinidine normalizes the open duration of slow-channel mutants of the acetylcholine receptor. NeuroReport 9, 1907–1911 (1998).
Fukudome, T., Ohno, K., Brengman, J. M. & Engel, A. G. AChR channel blockade by quinidine sulfate reduces channel open duration in the slow-channel congenital myasthenic syndrome. Ann. N. Y. Acad. Sci. 841, 199–202 (1998).
Google Scholar
Harper, C. M., Fukodome, T. & Engel, A. G. Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology 60, 1710–1713 (2003).
Google Scholar
García-Colunga, J., Awad, J. N. & Miledi, R. Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc. Natl Acad. Sci. USA 94, 2041–2044 (1997).
Google Scholar
Schara, U. & Lochmüller, H. Therapeutic strategies in congenital myasthenic syndromes. Neurotherapeutics 5, 542–547 (2008).
Google Scholar
Chaouch, A. et al. A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome. J. Neurol. 259, 474–481 (2012).
Google Scholar
Nayak, T. K. et al. Functional differences between neurotransmitter binding sites of muscle acetylcholine receptors. Proc. Natl Acad. Sci. USA 111, 17660–17665 (2014).
Google Scholar
Zarkadas, E. et al. Conformational transitions and ligand-binding to a muscle-type nicotinic acetylcholine receptor. Neuron 110, 1358–1370 (2022).
Google Scholar
Kediha, M. I., Tazir, M., Sternberg, D., Eymard, B. & Ali Pacha, L. Congenital myasthenic syndromes by Epsilon subunit mutations: phenotypic profiles of 17 Algerian families. Rev. Neurol. 181, 79–84 (2025).
Google Scholar
Li, H. et al. Autoimmune mechanisms elucidated through muscle acetylcholine receptor structures. Cell 188, 2390–2406 (2025).
Google Scholar
Beeson, D. & Newsom-Davis, J. in Channelopathies (eds Lehmann-Horn, F. & Jurkat-Rott, K.) 85–114 (Elsevier Science, 2000).
Wang, J. & Lindstrom, J. Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors. Br. J. Pharmacol. 175, 1805–1821 (2018).
Google Scholar
Burke, S. M. et al. Structural mechanisms of α7 nicotinic receptor allosteric modulation and activation. Cell 187, 1160–1176 (2024).
Google Scholar
Saito, A., Matsui, S., Chino, A., Sato, S. & Takeshita, N. Discovery and pharmacological characterization of novel positive allosteric modulators acting on skeletal muscle-type nicotinic acetylcholine receptors. Biochem. Biophys. Res. Commun. 668, 27–34 (2023).
Google Scholar
Ohno, K. et al. Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor ε subunit. Neuron 17, 157–170 (1996).
Google Scholar
Wang, H.-L. et al. Acetylcholine receptor M3 domain: stereochemical and volume contributions to channel gating. Nat. Neurosci. 2, 226–233 (1999).
Google Scholar
Sine, S. M. et al. Naturally occurring mutations at the acetylcholine receptor binding site independently alter ACh binding and channel gating. J. Gen. Physiol. 120, 483–496 (2002).
Google Scholar
Shen, X.-M., Brengman, J. M., Sine, S. M. & Engel, A. G. Myasthenic syndrome AChRα C-loop mutant disrupts initiation of channel gating. J. Clin. Investig. 122, 2613–2621 (2012).
Google Scholar
Dejthevaporn, C. et al. Treatment of slow-channel congenital myasthenic syndrome in a Thai family with fluoxetine. J. Clin. Neurosci. 96, 85–89 (2022).
Google Scholar
Gisselmann, G., Alisch, D., Welbers-Joop, B. & Hatt, H. Effects of quinine, quinidine and chloroquine on human muscle nicotinic acetylcholine receptors. Front. Pharmacol. 9, 1339 (2018).
Engel, A. G. et al. New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum. Mol. Genet. 5, 1217–1227 (1996).
Google Scholar
Shen, X.-M. et al. Mutations causing slow-channel myasthenia reveal that a valine ring in the channel pore of muscle AChR is optimized for stabilizing channel gating. Hum. Mutat. 37, 1051–1059 (2016).
Google Scholar
Arias, H. R., Feuerbach, D., Bhumireddy, P. & Ortells, M. O. Inhibitory mechanisms and binding site location for serotonin selective reuptake inhibitors on nicotinic acetylcholine receptors. Int. J. Biochem. Cell Biol. 42, 712–724 (2010).
Google Scholar
Arias, H. R., Bhumireddy, P. & Bouzat, C. Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors. Int. J. Biochem. Cell Biol. 38, 1254–1276 (2006).
Google Scholar
Roden, D. M., Woosley, R. L. & Primm, R. K. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am. Heart J. 111, 1088–1093 (1986).
Google Scholar
Whittington, C. J., Kendall, T. & Pilling, S. Are the SSRIs and atypical antidepressants safe and effective for children and adolescents? Curr. Opin. Psychiatry 18, 21–25 (2005).
Montgomery, S., Ferguson, J. M. & Schwartz, G. E. The antidepressant efficacy of reboxetine in patients with severe depression. J. Clin. Psychopharmacol. 23, 45–50 (2003).
Andreoli, V., Caillard, V., Deo, R. S., Rybakowski, J. K. & Versiani, M. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J. Clin. Psychopharmacol. 22, 393–399 (2002).
Arias, H. R., Ortells, M. O. & Feuerbach, D. (−)-Reboxetine inhibits muscle nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites. Neurochem. Int. 63, 423–431 (2013).
Google Scholar
Ohno, K. et al. Congenital myasthenic syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the epsilon subunit. Proc. Natl Acad. Sci. USA 92, 758–762 (1995).
Google Scholar
Milone, M. et al. Slow-channel myasthenic syndrome caused by enhanced activation, desensitization, and agonist binding affinity attributable to mutation in the M2 domain of the acetylcholine receptor α subunit. J. Neurosci. 17, 5651 (1997).
Google Scholar
Dwyer, T. M., Adams, D. J. & Hille, B. The permeability of the endplate channel to organic cations in frog muscle. J. Gen. Physiol. 75, 469–492 (1980).
Google Scholar
Sine, S. M. End-plate acetylcholine receptor: structure, mechanism, pharmacology, and disease. Physiol. Rev. 92, 1189–1234 (2012).
Google Scholar
Nicole, S. et al. Congenital myasthenic syndromes or inherited disorders of neuromuscular transmission: recent discoveries and open questions. J. Neuromuscul. Dis. 4, 269–284 (2017).
Google Scholar
Pham, M. C. et al. Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathol. 146, 319–336 (2023).
Google Scholar
Deflorio, C., Catalano, M., Fucile, S., Limatola, C. & Grassi, F. Fluoxetine prevents acetylcholine-induced excitotoxicity blocking human endplate acetylcholine receptor. Muscle Nerve 49, 90–97 (2014).
Google Scholar
Zhou, S. et al. Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis. Sleep 46, zsad177 (2023).
Google Scholar
Tanum, L. Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr. Scand. 101, 37–40 (2000).
Google Scholar
Rahman, M. M. et al. Structural mechanism of muscle nicotinic receptor desensitization and block by curare. Nat. Struct. Mol. Biol. 29, 386–394 (2022).
Google Scholar
Thompson, M. J., Mansoub Bekarkhanechi, F., Ananchenko, A., Nury, H. & Baenziger, J. E. A release of local subunit conformational heterogeneity underlies gating in a muscle nicotinic acetylcholine receptor. Nat. Commun. 15, 1803 (2024).
Google Scholar
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
Google Scholar
Punjani, A., Zhang, H. & Fleet, D. J. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. Nat. Methods 17, 1214–1221 (2020).
Google Scholar
Kimanius, D., Dong, L., Sharov, G., Nakane, T. & Scheres, S. H. W. New tools for automated cryo-EM single-particle analysis in RELION-4.0. Biochem. J. 478, 4169–4185 (2021).
Google Scholar
Pettersen, E. F. et al. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
Google Scholar
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D 66, 213–221 (2010).
Google Scholar
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D 60, 2126–2132 (2004).
Google Scholar
Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. Sect. D 66, 12–21 (2010).
Google Scholar
Sanchez-Garcia, R. et al. DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. Commun. Biol. 4, 874 (2021).
Google Scholar
Smart, O. S., Neduvelil, J. G., Wang, X., Wallace, B. A. & Sansom, M. S. P. HOLE: a program for the analysis of the pore dimensions of ion channel structural models. J. Mol. Graph. 14, 354–360 (1996).
Google Scholar
Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70–82 (2021).
Google Scholar
Pear, W. S., Nolan, G. P., Scott, M. L. & Baltimore, D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl Acad. Sci. USA 90, 8392–8396 (1993).
Google Scholar
Sine, S. M. Molecular dissection of subunit interfaces in the acetylcholine receptor: identification of residues that determine curare selectivity. Proc. Natl Acad. Sci. USA 90, 9436–9440 (1993).
Google Scholar
Mukhtasimova, N., daCosta, C. J. B. & Sine, S. M. Improved resolution of single channel dwell times reveals mechanisms of binding, priming, and gating in muscle AChR. J. Gen. Physiol. 148, 43–63 (2016).
Google Scholar
Colquhoun, D. & Sigworth, F. J. in Single-Channel Recording (eds Sakmann, B. & Neher, E.) 191–263 (Springer, 1983).
Sigworth, F. J. & Sine, S. M. Data transformations for improved display and fitting of single-channel dwell time histograms. Biophys. J. 52, 1047–1054 (1987).
Google Scholar
Source:
www.nature.com